
April 2 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CIRRUS-HCM FOUR-WEEK TRIAL OF EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM)
EDGEWISE THERAPEUTICS INC - EDG-7500 WAS GENERALLY WELL-TOLERATED
EDGEWISE THERAPEUTICS INC: INITIAL DATA READ-OUT FROM PART D IS EXPECTED IN SECOND HALF OF 2025
EDGEWISE: TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTIONS IN LVOT GRADIENTS IN PARTICIPANTS WITH OBSTRUCTIVE HCM
EDGEWISE THERAPEUTICS INC - PHASE 3 INITIATION PLANNED FOR FIRST HALF OF 2026